CALGARY, Alberta — November 26, 2025. Hemostemix Inc. has taken a major step in its global clinical-commercial expansion, announcing the acquisition of its first two cardiology practices under a new roll-up strategy designed to accelerate the deployment of its autologous stem-cell therapy ACP-01 (VesCell™). The Company has entered a binding Letter of Intent to acquire the practices of Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, two of the Dominican Republic’s most respected interventional cardiologists, each receiving 2,000,000 Hemostemix shares in exchange for their practices, subject to adjustment and TSXV approval. This milestone establishes Hemostemix’s first international clinical infrastructure, enabling a stronger commercial path for ACP-01 and expanding the Company’s footprint across key cardiovascular markets.
Science Significance
The acquisition anchors Hemostemix’s expansion strategy in the expertise of two clinicians who collectively have treated more than 200 patients with ACP-01, making them among the most experienced practitioners globally. Their hands-on experience spans angina, ischemic and dilated cardiomyopathy, congestive heart failure, peripheral arterial disease, chronic limb-threatening ischemia, and vascular dementia, all areas where ACP-01 has shown clinically relevant and statistically significant improvements in published studies. ACP-01 works by delivering autologous angiogenic cell precursors that promote neovascularization and tissue regeneration, targeting the microcirculatory deficits underlying advanced cardiovascular disease. Integrating ACP-01 into established cardiology practices enables direct observation, close patient follow-up, and improved data capture—strengthening scientific understanding of real-world outcomes.
Regulatory Significance
The roll-up strategy directly supports Hemostemix’s regulatory-compliant expansion, providing controlled clinical environments for ACP-01 therapy administration and enhancing oversight of treatment protocols. By embedding ACP-01 into licensed cardiology practices, the Company strengthens adherence to governance, documentation, traceability, and medical-oversight standards required for autologous cell-therapy products. The physicians’ commitment to facilitating regulatory approvals and coordinating with Dominican Republic health authorities provides Hemostemix with a structured pathway for future Phase II and Phase III trials, observational safety registries, and post-treatment monitoring. This infrastructure also supports the Company’s pathway for clinical activities in the Bahamas and upcoming expansion markets such as Florida, Puerto Rico, and Canada, where regulatory nuances differ but require consistent GCP-aligned execution.
Business Significance
Advertisement
The acquisition of two profitable, respected cardiology practices represents a transformational commercial milestone, creating a predictable patient-flow ecosystem for ACP-01 while providing a turnkey operational structure. Hemostemix now gains significant influence in physician-to-physician networks, enabling its sales team to leverage clinical credibility to expand practitioner adoption. With each acquired practice fully staffed, revenue-generating, and anchored by high-trust clinical reputations, Hemostemix reduces market-entry friction and accelerates ACP-01 commercialization. The move complements the Company’s broader financial activities, including a recent TSXV-approved extension for its private placement financing, which has raised over $461,000 to support ongoing operations and regulatory preparations.
Patients’ Significance
For patients suffering from end-stage cardiovascular disease, often deemed “no-option” cases, the integration of ACP-01 into local cardiology practices offers new access to a therapy associated with 0% mortality, reduced pain, and wound healing rates up to 83% in long-term follow-ups from previous clinical evaluations. Establishing dedicated, ACP-01-enabled cardiology centers ensures continuity of care, improved monitoring, and streamlined referral pathways—critical for conditions such as CLTI, cardiomyopathy, and chronic ischemia. Patients benefit from proximity, clinical oversight, and confidence that treatment is delivered within a standardized, medically supervised environment.
Policy Significance
The expansion reflects broader policy interest in regenerative medicine deployment, especially in regions facing rising burdens of cardiovascular disease and limited access to advanced therapies. By acquiring practices within active clinical jurisdictions such as the Dominican Republic and soon Florida, Hemostemix positions itself to leverage compassionate-use pathways, state-specific cell-therapy legislation, and emerging regulatory frameworks enabling earlier patient access. This strategy aligns with public-health goals to reduce amputations, hospitalizations, and long-term disability linked to ischemic disease while broadening the infrastructure required to support evidence-based regenerative medicine in diverse healthcare systems.
Hemostemix’s acquisition of its first two cardiology practices marks a pivotal turning point in the Company’s evolution from a clinical-stage innovator into an integrated cell-therapy provider with global reach. By combining ACP-01 clinical expertise, established practice infrastructure, and a scalable roll-up model, Hemostemix is now positioned to accelerate patient access, strengthen regulatory readiness, and build a durable commercial pathway across the Americas. As further practices are added and clinical programs expand, this strategy may set a new precedent for how regenerative-medicine companies bridge the gap between clinical efficacy and real-world adoption.
Source: Hemostemix Inc. press release
